Investor Service Announcement no.2/2011


To: NASDAQ OMX Copenhagen
Hørsholm, Denmark, May 4, 2011




LifeCycle Pharma A/S to Host Conference Call Announcing

Result for the first quarter 2011


LifeCycle Pharma A/S (OMX: LCP) will announce the result for the first quarter
2011 on Tuesday May 10, 2011 after 5 PM. LCP's Management will host a
conference call on May 11, 2011, at 3:00 PM CET (Denmark); 2:00 PM GMT
(London), 9:00 AM ET (New York), 6:00 AM PT (San Francisco) to discuss the
financial results.


To access the live conference call, please dial one of the following numbers:

+45 32 72 76 25 Denmark

+44 (0) 1452 555 566 UK

+1 631 510 7498 USA

Access code 64356225


Following the conference call, an audio cast will be available on the company's
website www.lcpharma.com until June 10, 2011. A presentation will be available
on LCP's website (under ‘Investors') one hour prior to the scheduled time of
the conference call.


For more information, please contact:



LifeCycle Pharma A/S Johnny Stilou
John Weinberg, M.D. CFO
SVP, Commercial Operations & Investor Relations Phone: + 45 2055 3817
Phone: +1 732 321 3208 Email: [email protected]
Email: [email protected]


About LifeCycle Pharma A/S (LCP)

Based in Hørsholm, Denmark, with an office in New Jersey, LCP is a specialty
pharmaceutical company. Clinical development is the core of LCP's efforts to
develop a product portfolio which includes the Company's lead product
candidate, LCP‐Tacro™, for immunosuppression, specifically organ
transplantation, and products to combat certain cardiovascular diseases. LCP
adapts new technologies on a fast commercial timetable. LCP's unique, patented
delivery technology, MeltDose®, can improve absorption and bioavailability ‐ at
low‐scale up costs ‐ not only for a broad spectrum of drugs already on the
market but also for new chemical entities. LCP has a lipid lowering product,
Fenoglide®, currently on the U.S. market and a diversified near and medium term
pipeline with three clinical stage product candidates and a number of projects
in preclinical development. LCP is listed on the NASDAQ OMX Copenhagen under
the trading symbol OMX: LCP. For further information, please visit
www.lcpharma.com

04052011 LifeCycle Pharma Host Q1 2011 Interim Report Conference Call.pdf